PD-L1/PD-1 Cancer Immunotherapy and New Targets - Gordon Freeman, PhD
1:00:33
Antibody responses to SARS-CoV-2 infection and vaccination - Florian Krammer Ph.D.
4:27
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
1:09:19
Cancer immunotherapy - significant breakthrough or unrealised potential?
37:26
Cancer Immunotherapy Basics: Understand the science behind this cutting-edge treatment
39:06
Expanding the Benefits of Immuno-Oncology Through Novel Rational Targets and Combinations
1:00:44
Targeting Cancer Pathways: Understanding Immune Checkpoints
1:00:50
Deciphering Immuno-oncology: Targeting Innate Immunity in Cancer
58:49